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Biochemical and functional characteristics of the 
human leukocyte membrane antigen family LFA-1, 
Mo-1 and pl50,95*
The human leukocyte function-associated (LFA-1) antigen, the monocyte differentia­
tion antigen Mo-1 which is characterized as the C3bi receptor and the glycoprotein 
p i50,95 are characterized biochemically. Immunoprecipitations carried out with 6 
different monoclonal antibodies (mAb) against LFA-1 indicated that four mAb (SPV- 
L l, SPV-L5, SPV-L7 and SPV-L11) were directed against the a chain, whereas mAb 
CLB54 and MHM-23 were found to react with the common |3 chain of LFA-1, Mo-1 
and p 150,95. LFA-1 and Mo-1 expressed on KG-1 cells or lymphocytes, monocytes 
and granulocytes from one donor were homogeneous. Interestingly the a chain of 
pl50,95 showed heterogeneity. The molecular weight of the a  chain expressed on 
monocytes was consistently higher than that of the a chain on granulocytes. The |3 
subunits of LFA-1 and Mo-1 (as detected by mAb Bear-1) are not only similar in 
molecular weight and isoelectric focusing patterns, but it is demonstrated here that 
they are also identically glycosylated and have similar protein backbones as judged by 
tryptic peptide mapping. In spite of their structural similarities, LFA-1 and Mo-1 
differ completely in some of their biological functions, Anti-LFA-1 mAb strongly 
inhibited monocyte-dependent T cell proliferation induced by tetanus toxoid or Helix 
pomatia hemocyanin and pokeweed mitogen-driven specific antibody production in 
vitro, whereas the anti-Mo-1 antibody Bear-1 was ineffective. These results suggest 
that the differences in these biological functions of LFA-1 and Mo-1 may be related to 
their different a  subunits, which may recognize specific counter structures,
1 Introduction
The human leukocyte function associated (LFA-1) antigen, 
the monocyte differentiation antigen Mo-1 which is character­
ized as the C3bi receptor and the glycoprotein termed pl50,95 
belong to a family of related human leukocyte membrane anti­
gens. LFA-1 is expressed on lymphocytes, monocytes and 
granulocytes [1], whereas Mo-1 and pl50,95 are present on 
monocytes, granulocytes and “null” cells [2], Recently, it has 
been shown that these molecules contribute to the adhesion 
reaction of these cells. Blocking experiments with anti-LFA 
monoclonal antibodies (mAb) demonstrated that LFA-1 
inhibits the adhesion step between effector and target cells in 
cytotoxic T lymphocyte, natural killer and lectin-dependent 
cellular cytotoxicity [1, 3,4], LFA-1 also participates in mono- 
cyte-dependent lectin-induced T cell proliferation suggesting 
that it also acts as an adhesion molecule between monocytes 
and T cells.
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Abbreviations: HPH: Helix pomatia hemocyanin IEF: Isoelectric 
focusing LFA-1: Leukocyte function-associated antigen-1 MM: 
Molecular mass mAb: Monoclonal antibody(ies) NMS: Normal 
mouse serum SDS: Sodium dodecyl sulfate PAGE: Polyacrylamide 
gel electrophoresis pfc: Preformed complex PWM: Pokeweed 
mitogen TPA: 12-O-tetradecanoyl phorboI-13-acetate TT: Tetanus 
toxoid Endo-F: Endo-p-N-acetyl-glucosaminidase F ELISA: En­
zyme-linked immunosorbent assay RAM: Rabbit anti-mouse
Mo-1, which is the receptor for the inactivated form of C3b, 
mediates the adhesion of soluble complexes or particles selec­
tively opsonized with C3bi [5, 6]. The third member of this 
family, p i50,95, is less well investigated but studies in patients 
with an inherited LFA-1, Mo-1 and pl50,95 deficiency syn­
drome indicated that this molecule, probably similarly to 
LFA-1 and Mo-1, is associated with the adhesion of granulo- 
cytes [7]. In addition to their functional similarities these anti­
gens are also structurally related, Each antigen is composed of 
an a and |3 subunit which are noncovalently associated. The |3 
chains of all three molecules have a molecular mass (MM) of 
95 kDa and have been shown to be similar [8]. The a chains of 
LFA-1, Mo-l and pl50,95 have different MM of 170,165 and 
150 kDa, respectively.
In the present study, 6 different mAb directed against the a or 
|3 chain of LFA-1 were used for the biochemical characteriza­
tion of LFA-1, Mo-1 and pl50,95 expressed on the human 
myeloblastic cell line KG-1. In addition, the heterogeneity of 
these molecules expressed on lymphocytes, monocytes and 
granulocytes derived from one donor was investigated. Our 
findings indicate that only the a chain of pl50,95 showed 
heterogeneity. Finally we extended the findings of Sanchez- 
Madrid et al. [8] by demonstrating that the (3 subunits of LFA- 
1 and Mo-1 in addition to their similarities in MM and isoelec­
tric focusing (IEF) patterns were identically glycosylated and 
had similar protein backbones as judged by tryptic peptide 
mapping. In spite of these structural similarities and the fact 
that both molecules act as adhesion molecules on granulo­
cytes, it is reported here that both molecules differ completely 
in other biological functions. Anti-LFA-1 antibodies strongly 
inhibited monocyte-dependent antigen-specific T cell prolifer­
ation and pokeweed mitogen (PWM)-driven specific antibody 
production in vitro, whereas the anti-Mo-1 antibody, Bear-1, 
produced in our laboratory was ineffective.
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2 Materials and methods
2.1 Cells
)
H u m a n  leukocytes were isolated from a buffy coat from blood 
o f  healthy volunteer donors by centrifugal élutriation [9], 
M onocytes, or monocyte subsets and granulocytes obtained in 
th is  way, were >95% pure, whereas lymphocytes were 
o b ta in e d  at a purity of 99.9% [9], The myeloblastic cell line 
KG-1 [10] was maintained in RPMI 1640 containing 10% fetal 
c a lf  serum, sodium  pyruvate (50 mg/ml), L-glutamine 
(2 X 10“3 M) and penicillin (100 IU)/streptomycin (100 [xg/ml). 
T h is  cell line was kindly provided by Dr. Robert F. Todd III 
(D ana-Farber Cancer Institute, Boston, MA). KG-1 cells 
w e re  stimulated with 10  ng/ml 12-O-tetradecanoyl phorbol-13- 
a c e ta te  (TPA, batch 028, Midland Corporation, NY) for three 
d ay s  and restimulated every third day with 5 ng TP A. In this 
w ay  adherent macrophage-like cells were obtained [11].
2.2 mAb
T h e  mAb SPV-L1, SPV-L3, SPV-L5, SPV-L7 and SPV-L11 
w e r e  obtained by immunization of BALB/c mice with cells of 
th e  T 4 +T8“ cytotoxic T lymphocyte clone HG-38 [12]. The 
an tibodies were selected for inhibition of T cell-mediated kill­
in g  b y  screening of the hybridoma supernatants 10-14 days 
a f t e r  the fusion. CLB54 (LFA-1/1) was selected in a similar 
w a y , and is directed against the (3 chain of LFA-1, Mo-1 and 
p !5 0 ,9 5  [13]. Anti-Mo-1, reactive with human monocytes, null 
c e l ls ,  granulocytes, bone marrow cells and malignant myeloid 
ce lls  [2, 14], was a gift from Dr. Robert F, Todd III (Dana 
F a r b e r  Cancer Institute, Boston, MA). Bear-1, Rupi-1 and 
R u p i-5  were obtained by immunization of BALB/c mice with 
h u m a n  monocytes isolated by centrifugal élutriation. Bear-1 
precipitated a 165-95-kDa complex and was found to be simi­
la r  to  Mo-1 (not shown). Rupi-1 reacts with a 35-kDa myeloid 
differentiation antigen expressed on human monocytes, 
granulocytes and myeloid leukemia cells. mAb Q5/13 is 
d irec ted  against HLA-DR and was kindly provided by Dr. 
So ldano  Ferrone (New York Medical College, Valhalla, NY). 
M H M 23 which is directed against the |3 chain of LFA-1 was a 
g ift o f  Dr. A. McMichael (Nuffield Dept., John Radcliffe Hos­
p i ta l ,  Oxford, GB).
2 .3  Radiolabeling and immunoprécipitation
C e ll  surface radioiodination with Na125I (ICN Radiochemicals, 
I rv in e , CA) was catalyzed by l,3,4,6-tetrachloro-3a, 6a- 
diphenylglycoluril (Iodogen, Pierce Chemical Co., Rockford, 
IL )  [15]. For immunoprécipitation, radiolabeled cells were 
ly sed  with 1% Nonidet-P40 in 0.01 M triethanolamine-HCl, 
p H  7.8, 0.15 m  NaCl, 1 mM phenylmethylsulfonyl fluoride, 
0 ,0 2  mg/ml ovomucoid trypsin inhibitor (Sigma Chemical Co., 
S t. Louis, MO; TEA/NaCl buffer). Nuclear debris was 
rem oved from the lysates by centrifugation at 13 000 X g for
15 min at 4°C. Material insoluble in the lysis buffer was 
rem oved by centrifugation at 100000 x g for 30 min in an air- 
driven centrifuge (Beckman Instruments, Palo Alto, CA). 
Lysates were precleared further by successive incubations with 
formalin-fixed Staphylococcus aureus bacteria (strain Cowan 
I) and preformed complex of mouse Ig and rabbit anti-mouse 
Ig> as described previously [16]. Precleared lysates were incu­
b a te d  for 3 - 4  h with a preformed complex made with the
specific mAb and rabbit anti-mouse Ig? and immunoprecipi- 
tates were removed from the lysates by centrifugation at
13 000 x g. Precipitates were resuspended in 0,2 ml TEA/NaCl 
buffer with 0.5% sodium deoxycholate and spun through a 
discontinuous gradient consisting of 0 .4  ml of 1 0% sucrose,
0.5% Nonidet-P40 in TEA/NaCl buffer, and 0.8 ml of 2 0 % 
sucrose in the same buffer without detergents, at 13 000 X g for
15 min. Subsequently, immunoprecipitates were washed once 
in 0.01 MTEA-HC1, pH 7,8, 0 .2 % Nonidet-P40.
2.4 Enzyme treatment
Endo-p-N-acetylglucosaminidase F (Endo-F) was kindly sup­
plied by Drs. John Elder and Stephen Alexander (Scripps 
Clinic, La Jolla, CA). Endo-F treatment was performed 
directly on the immune complex. The protein was resuspended 
in 0.1 M sodium phosphate buffer, pH 6.1, containing 50 mM 
EDTA, 1 % 2-mercaptoethanol, 0 .1% sodium dodecyl sulfate 
(SDS) and boiled for 2 min. Then, Nonidet-P40 was added to 
1% and samples were incubated with Endo-F for 2 h at 37 CC, 
as described by Elder and Alexander [17].
2.5 Electrophoresis and autoradiography
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out on discontinuous vertical slab gels according to a 
modification of the Laemmli procedure [18]. Gradient gels 
were made either 5-15% or 10-15% in acrylamide. Two- 
dimensional gel electrophoresis was done in accordance with 
the method of O’Farrell [19]. For IEF, ampholytes (LKB, 
Bromma, Sweden) of pi 3.5-10, 4-6 and 5-8 as 1:1:4 were 
used in sample buffer and gel. Samples were taken up in 8 .8  M 
urea, 0.4% SDS, 5% 2-mercaptoethanol, 0.2% ampholytes. 
After 45 min, an equal volume of 8 .8  M urea, 2% Nonidet- 
P40, 5% 2 -mercaptoethanol, 2 % ampholytes was added and 
electrophoresis performed. The second dimension consisted of 
a 5-7.5% SDS-polyacrylamide gel. Kodak XAR-5 film was 
used in combination with intensifier screens (Cronex Light­
ning Plus, Dupont Chemical Co., Newton, CT) for autoradio­
graphy of 125I-labeled materials.
2 .6  Peptide mapping
To perform two-dimensional peptide mapping, specific bands 
were cut out of gels that previously had been stained, de­
stained and autoradiographed. The gel slices were washed in 
destain solution (acetic acid, ethanol, water as 7.5:20:72.5), 
then methanol, and lyophilized. Per gel slice, 25 jxg trypsin 
(TPCK, 217 U/g, Worthington, Millipore Co., Freehold, NJ) 
was added in 0.05 M NH4HCO3 and slices were incubated for
16 h at 37 °C. Trypsin digestion was repeated once. Combined 
samples were lyophilized, taken up in water and lyophilized 
again. The dry protein was dissolved in 50% pyridine and 
electrophoresis was performed on cellulose TLC plates 
(no. 5502, E. Merck, Darmstadt, FRG) in pyridine, acetic 
acid, water ( 1 : 1 0 :89), pH 3.5. Chromatography was done in 
the second dimension with pyridine, acetic acid, n-butanol, 
water (10:3:15:12) as running fluid.
2.7 Lymphocyte proliferation assay
The antigen-induced lymphocyte proliferation assays were car­
ried out in serum-free medium as described [20]. Two x 105 LF
1144 G. D. Keizer, J. Borst, C. G, Figdor et ai. Eur. J. Immunol. 1985.15: 1142-1147
cells from donors primed with Helix pomatia hemagglutinin 
(HPH) or boosted with tetanus toxoid (TT) were cultured in 
triplicate in microtiter wells (Costar, Cambridge, MA, 
no, 3596) in the presence of HPH (10 ng/ml) or TT (1 LF/ml). 
These concentrations of antigens have been shown to be opti­
mal in these tests [21], Monocytes isolated by centrifugal elut- 
riation were added in concentrations of 2 x 104 (10%) or 
5 X 103 (2.5%). mAb were added in a final dilution of 1:200 
and were present throughout the culture period. The cell mix­
tures were cultured in a final volume of 0.2 ml for 7 days at 
37 °C in a humidified atmosphere with 5% C 02. Twenty |xl 
containing 0.4 [xCi = 14.8 kBq tritiated thymidine ([3H]dThd) 
was added during the last 4 h of incubation. The cultures were 
harvested with an automatic cell harvester, MASH-II, and 
counted as described previously [3].
2.8 Lymphocyte cultures for antibody production
The lymphocyte cultures for antibody synthesis were also car­
ried out in serum-free medium. Three X 105 LF cells obtained 
from donors primed with HPH or boosted with TT were cul­
tured in 2-ml wells (Costar no. 3424). The purified monocytes 
were added in concentrations of 3 x 105 monocytes/well 
(10%). The cell mixtures were cultured in a final volume of 
1.5 ml medium and contained PWM at a final concentration of 
1:400 (v/v). They were incubated at 37 °C in a humidified 
atmosphere of 5% C 0 2 for 8 days. After this incubation 
period the supernatants were harvested and specific antibody 
production was measured in an indirect enzyme-linked 
immunosorbent assay (ELISA).
2.9 ELISA for antibody production in vitro
Specific antibody production in the lymphocyte cultures was 
measured in an ELISA as described elsewhere [22], The bot­
toms of 0.2 ml microtiter wells (Sterilin, Teddington, GB, no. 
M23AR) were coated with HPH or TT. One hundred \i\ of 
supernatant was tested in duplo and compared to a serum 
standard diluted 1:400 and 1:800 for HPH and 1:600 and 
1:1200 for TT. After an incubation period of 45 min at 37 °C 
the wells were washed 3 times and 100 \i\ of peroxidase-conju­
gated rabbit anti-human IgA, IgG, IgM, \  and % (Dako, 
Copenhagen, Denmark) was added. After incubation and 
washing, 100 p.1 0.05 M phosphate-buffered (pH 5.6) o-pheny- 
lenediamine dihydrochloride (0.2 mg/ml) was added in the 
presence of 0.045% (v/v) H20 2. After 45 min incubation at 
37 °C the reaction was stopped with 1 N H2S04 and the extinc­
tions were measured in a multichannel spectrofotometer 
(Titertek). The absorbance values of the supernatants were 
compared with those of the serum standards. The antibody 
present in the supernatants was quantitated by probit analysis 
using the absorbance of the highest serum standard concentra­
tions arbitrarily assigned a value of 100 Units/ml
3 Results
3.1 Biochemical characterization of LFA-1 with different 
anti-LFA-1 mAb
It has been demonstrated recently that LFA-1, Mo-1 and 
pl50,95 belong to a family of related human leukocyte mem­
brane glycoproteins. These antigens consist of an a and |3
chain which are noncovalently associated. The (3 chains of each 
of these antigens have been shown to be similar in MM and 
IEF pattern [8]. This implies that mAb directed against the |3 
chain of LFA-1 also will precipitate Mo-1 and pl50,95 from 
monocytes and granulocytes. To investigate whether the vari­
ous mAb directed against LFA-1 were directed against the a 
or P chain of this molecular complex, immunoprécipitations 
were carried out with 125I-labeled lysates of the monoblastic 
cell line KG-1. The mAb SPV-L1, SPV-L5, SPV-L7 and SPV- 
L ll  precipitated 2 bands of 170 kDa (a chain) and 95 kDa ((3 
chain) indicating that these antibodies were directed against 
the a chain. In contrast, mAb CLB54 and MHM-23 detected 
an additional band of 150 kDa (Fig. 1). The 165 kDa band is 
also precipitated from KG-1 (Fig. 2) but not detectable in a 
broad 170-kDa a  chain of LFA-1 (Fig. 1). This is established 
in Fig. 3 in which it is shown that MHM-23 and CLB54 indeed 
precipitated four proteins from 125I-iabeied monocyte lysates 
of 170, 165, 150 and 95 kDa, respectively. Similar reaction 
patterns were observed by Springer et al. [8] with the mAb 
TS1/18 which was shown to be directed against the |3 chain of 
LFA-1. Therefore, our results indicate that CLB54 and MHM- 
23 are directed against the (3 chain of LFA-1, Since the (3 
chains of LFA-1, Mo-1 and pl50,95 are similar [8], the 165- 
kDa and 150-kDa bands precipitated from monocytes and
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Figure 1. Precipitation of LFA-1 from a 125I-labeled lysate of the 
monoblastic cell line KG-1 with various anti-LFA-1 antibodies. The 
lysate was precleared three times with rabbit anti-mouse-normal 
mouse serum preformed complex (RAM-NMS pfc) and divided into 
six equal portions, followed by immunoprécipitation with pfc of the 
antibodies mentioned below. Immunoprecipitates were subjected to 
SDS 1.5% PAGE and autoradiography. (A) SPV-L1; (B) CLB54; (C) 
SPV-L5; (D) SPV-L7; (E) SPV-L11; (F) MHM-23; (G) RAM-NMS 
pfc (control).
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Figure 2. Precipitation of LFA-1 
and Mo-1 from 125I-Iabeled ly­
sates from unstimulated and 
TPA-stimulated KG-1 cells. Ly­
sates were precleared repeatedly 
with nonspecific pfc followed by 
precipitation with specific pfc.
(A) Bear-1 precipitated from a 
125I-labeled lysate of monocytes.
(B) RAM-NMS pfc control, 
TPA-treated cells (TTC). (C) 
Bear-1 (recognizing Mo-1 anti­
gen) TTC. (D) SPV-L7 (recog­
nizing LFA-1 antigen) TTC. (E) 
Bear-1 from unstimulated cells 
(UC). (F) SPV-L7 (UC). (G) 
RAM-NMS pfc UC (control).
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KG-1 cells represent the a  chains of Mo-1 and pl50,95, respec­
tively. No differences in MM of the a and (3 chains of LFA-1 
w ere observed, indicating that the LFA-1 antigens precipi­
ta ted  by the various anti-LFA-1 antibodies were not 
heterogeneous*
3 ,2  LFA-1 and Mo-1 on KG-1 cells induced to differentiate 
with TP A
KG-1 can be induced to differentiate to monocytes by the 
phorbol ester TP A [11]. Immunoprécipitations carried out 
w ith radiolabeled lysates of KG-1 cells before and after TPA- 
induced differentiation showed a strong increase in the a and (3 
chains of Mo-1 (Fig. 2). These results confirm immuno­
fluorescence data which demonstrated that the expression of 
Mo-1 was strongly enhanced after incubation with TPA (De 
Vries et al., manuscript in preparation). The low expression of 
Mo-1 on the nonstimulated KG-1 cells also explains why the 
Mo-1 a chain is difficult to detect in the immunoprecipitates 
obtained with CLB54 and MHM-23 from KG-1 cells shown in 
Fig. 1, whereas the LFA-1 a chain is present as a very strong 
band.
3.3 Biochemical characteristics of LFA-1 and Mo-1 on 
lymphocytes, granulocytes and monocytes
T o investigate whether LFA-1 was heterogeneous on different 
cells derived from the same donor, immunoprécipitations were 
carried out with 125I-labeled lysates of monocytes, granulo­
cytes and lymphocytes, and the mAb SPV-L7, Bear-1 and 
CLB54. The a and |3 chains of LFA-1 and Mo-1 expressed on 
monocytes, granulocytes and lymphocytes containing null cells 
have identical MM indicating that LFA-1 and Mo-1 on the 
different cells are not heterogeneous (not shown). Interest­
ingly, heterogeneity was observed in the MM of the a  chain of 
pl50,95 in the immunoprecipitates obtained with the mAb 
CLB54 (Fig. 3), which is directed against the (3 chain of LFA-
1. The MM of the a chain of p i50,95 expressed on monocytes 
is higher than that of the a chain expressed on granulocytes
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Figure 4. Two-dimensional gel electrophoresis of 125I~labeled antigens 
of Mo~l (A) and LFA-1 (B) detected by Bear-1 and SPV-L7, respec­
tively, according to O'Farrell [18] using a 5-7,5%  gel in the second 
dimension. The 110-kDa band observed in the immunoprecipitates of 
SPV-L7 is due to proteolytic breakdown of the LFA-1 a chain.
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Figure 5, Analysis by SDS 
5-7.5% PAGE of Mo-1 and 
LFA-1 treated with Endo-F. 
Monocytes were labeled with l25I 
as described in Sect. 2.7, and 
Bear-1 and SPV-L7 immuno­
precipitates were subjected to di­
gestion with Endo-F (+ ), or in­
cubated in the absence of en­
zyme (-). The proteins were 
recovered by precipitation with 
10% trichloroacetic acid and an­
alyzed on a 10% polyacrylamide 
gel. (A) RAM-NMS preclear; 
(B) Bear-1 (+); (C) Bear-1 (-); 
(D) SPV-L7 (+); (E) SPV-L7 
(-).
from the same donor, where it was shown to precipitate a 140- 
kDa band.
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g Figure 3. Precipitation with
CLB54, which recognizes the 
common (3 chain, from 125I- 
labeled monocytes, granulo­
cytes and lymphocytes (con­
taining “null” cells) derived 
from one donor. Lymphocytes, 
three monocyte subsets which 
differ in density and function 
[9], and granulocytes were ob­
tained by centrifugal élutria­
tion (purity >95% ), labeled 
and precleared three times with 
RAM-NMS pfc. Subsequently, 
precipitations with CLB54 or 
MHM-23 (anti-p chain) were 
carried out, followed by wash­
ing and SDS 5-7,5% PAGE. 
For reasons unknown, one of 
the monocyte fractions labeled 
poorly with 125I (lane E ). (A) 
MHM-23; (B-F) CLB54 from 
granulocytes, three monocyte fractions and-lymphocytes, respectively. 
(G) RAM-NMS as control.
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3.4 Comparison of the molecular complexes detected by Bear-1 
and anti-LFA-1
Sanchez-Madrid et al. [8] have shown a high degree of similar­
ity between Mo-1 and LFA-1. Although the a chains of Mo-1 
and LFA-1 had different MM of 170 and 165 kDa, respec­
tively, the (3 chains were shown to be similar in MM and IEF 
pattern. We extended these results by demonstrating that the 
(3 chain of LFA-1 and Mo-1 [2, 14] (as detected by the mAb 
Bear-1 produced in our laboratory) not only had similar MM 
and IEF patterns (Fig. 4), but they were also identical as 
judged by their glycosylation and tryptic peptide mapping. 
Enzymatic digestion of the |3 chains of LFA-1 and Mo-1 with 
Endo-F, which cleaves off all N-linked sugars via hydrolysis of 
the glycosidic bond of the N-N-diacetylchitobiose core struc­
ture [17], resulted in an identical reduction in MM from 
94 kDa to 90 kDa approximately (Fig. 5). These results indi­
cated that the degree of N-linked glycosylation of both |3 
chains is identical and that both |3 chains are equally sensitive 
to Endo-F treatment. In contrast Endo-F treatment of the a 
chains resulted in reaction products of different MM, indicat­
ing that the differences in the a chains were not related to 
differences in N-linked glycosylation.
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Figure 6. Tryptic peptide map of 125I-labeled antigens of Mo-1 and 
LFA-1. Specific bands cut out from autoradiographed gels were 
treated as described in Sect. 2,6. (A) LFA-1 a (left); Mo-1 a (right); 
(B) LFA-1 (3 (left); Mo-1 (3 (right).
To establish that the protein backbones of the |3 chains of 
LFA-1 and Mo-1 are identical, tryptic peptide maps of both (3 
chains were prepared. In Fig. 6 it is shown that the peptide 
composition of the (3 chains of both antigens are identical, 
whereas that of the a  chains differed completely.
3.5 Biological properties of Mo-1 and LFA-1
Mo-1 and LFA-1 have similarities in biochemical structure and 
identical ¡3 chains. In addition it has been shown that both 
molecules act as adhesion molecules on granulocytes [7, 23, 
24]. However, Mo-1 and LFA-1 have different a chains and 
are distributed on different cell types. Therefore, we investi­
gated whether these antigens differed in other biological func­
tions. Since LFA-1 and Mo-1 are both expressed on human 
monocytes, the effects of SPV-L5 and Bear-1 on monocyte- 
dependent reactions, like antigen-specific lymphocyte prolifer­
ation and PWM-driven specific antibody production in vitro, 
were investigated [21]. It was shown that both processes are 
monocyte dependent. Antigen-specific lymphocyte prolifera­
tion was strongly reduced after the monocytes had been 
depleted by centrifugal élutriation (Table 1). The proliferative 
responses were completely restored by the addition of 10% 
autologous monocytes. The PWM-driven specific antibody 
production was completely absent after removal of the mono­
cytes; however, also in this situation specific antibody produc­
tion could be restored to control levels by the addition of 10% 
autologous monocytes (Table 1). Interestingly, the antigen- 
specific proliferative response and the PWM-driven specific 
antibody production in vitro were inhibited by mAb directed 
against LFA-1, whereas Bear-1 and anti-Mo-1 had no effect
Table 1. Monocyte dependence of antigen-induced lymphocyte proliferation and specific antibody production after PWM stimulation^
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a) Four different donors were immunized with TT (donor 1 and 2) or HPH (donor 3 and 4). Several days (19-60) after immunization, specific 
lymphocyte proliferation or specific antibody production after PWM stimulation against TT or HPH was measured. Lymphocytes were depleted 
of monocytes by centrifugal élutriation [9], and contained less than 0.1% monocytes as judged by staining for nonspecific esterase. The amount 
of surface Ig+ cells was 5% (donor 1) and 7% (donor 4). Monocytes were added in a final concentration of 10%.
b) NT = Not tested.
Table 2. Effects of mAb against LFA-1 and Mo-1 on antigen-induced lymphocyte proliferation^
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(35-kDa myeloid differentiation antigen) were added to a final concentration of 1:200 of ascites.
a) Three different donors were 
immunized with TT (donor 1 
and 2) or HPH (donor 3). In 
vitro stimulation of lympho­
cytes supplemented with 10% 
autologous monocytes resulted 
in lymphocyte proliferation. 
The mAb SPV-L5 (anti-LFA- 
la ), Bear-1 (anti-Mo-la), Q5/ 
13 (anti-HLA-DR), SPV-L3 
(anti-HLA-DC) and Rupi-1
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Table 3. Effects of mAb against LFA-1 and Mo-1 on the PWM-driven specific antibody production^ a) Two different donors were im­
munized with TT (donor 1) or 
HPH (donor 4). In vitro stimula-
i | | | | | i i0 r  Specific antibody production (U/ml) tion of lymphocytes supplemented
— AU- C<mjr-L5 Bear-1 Q5/13 SPV-L3 Rupi-1 Í with 10% autologous monocytes
& o . . \
V."', .• \ \
1 with PWM resulted in antibody
7  ±  6.3 0,8 ± 0 .2  40.4 ±7.1 0.1 ± 0 .1  0.2 ±0 .1  47.1 ± 4 .6  production against TT (donor 1) or
<
I I H S P ;t  13.7 +  1.8 0 .4±0 .1  13.1 ± m : ::m L 4 ± 0.3 0.8 ±0.3  14 .0 ± 2,1 HPH (donor 4). The antibody pro-
duction was measured with an 
ELISA (see Sect, 2.9). For mAb 
used see Table 2.
(Tables 2 and 3). Furthermore, it is shown that the mAb Q5/13 
(anti-HLA-DR) and SPV-L3 (anti-HLA-DC) completely 
inhibited the antigen-specific T ceil proliferation and antibody 
production in vitro. The mAb Rupi-1 which detects a 35-kDa 
differentiation antigen only present on human monocytes and 
granulocytes was ineffective (Tables 2 and 3). These results 
indicate that in spite of their identical |3 chains, LFA-1 and 
Mo-1 differ in their biological functions. LFA-1 is apparently 
associated with monocyte-T cell interaction, whereas Mo-1 is 
not.
4 Discussion
In this study the biochemical and biological characteristics of 
LFA-1, Mo-1 and p150,95 were investigated. All three anti­
gens are only expressed on human monocytes, granulocytes 
and “null5* cells, whereas LFA-1 is also present on human 
thymocytes and on resting and activated T and B cells [1, 2], 
The monocyte differentiation antigen Mo-1, which was charac­
terized as the receptor for the inactivated form of C3b, was 
analyzed with a mAb Bear-1. Precipitations of LFA-1 from 
monocytes, granulocytes and KG-1 carried out with 6 different 
mAb directed against LFA-1 showed that all 6 antibodies pre­
cipitated the same bimolecular complex with an a chain of 
170 kDa and a (3 chain of 95 kDa from KG-1 cells. Four of 
these antibodies (SPV-L1, SPV-L5, SPV-L7 and SPV-L11) 
were directed against the a  chain. The two other mAb (CLB54 
and MHM-23) were directed against the |3 chain of LFA-1, 
which was reported to be similar to the (3 chains of Mo-1 and 
pl50,95 [8]. Therefore, the immunoprecipitates of these anti­
bodies and radiolabeled lysates of monocytes, granulocytes 
and KG-1 also contained the 165-kDa a chain of Mo-1 and the 
150-kDa chain of pl50,95. In addition, immunoprécipitations 
carried out with SPV-L7 (anti-LFA-1 a chain), Bear-1 (anti- 
Mo-1 a  chain) (both not shown), CLB54 (anti-LFA-1|3 chain) 
and radiolabeled lysates of lymphocytes, monocytes and 
granulocytes isolated from the same donor revealed no 
heterogeneity in the a chains of LFA-1 and Mo-1 expressed on 
the various cell types. Interestingly, the a chain of the pl50,95 
molecule was found to be heterogeneous. The p i50 a chain on 
monocytes was consistently found to have a higher MM than 
the a chain on granulocytes derived from the same donor. The 
nature of these differences in MM of pl5Q a chains remains to 
be determined. However, recently we observed that the 
p 150,95 glycoprotein is associated with the chemotaxis of 
human monocytes and the adherence of these cells to plastic 
surfaces and substrates consisting of endothelial cells*. In con­
trast to their association with adherence of granulocytes, LFA- 
1 and Mo-1 were not involved in the adherence of monocytes*. 
Sanchez-Madrid et al, [8] were the first to demonstrate that
* G. D, Keizer, manuscript in preparation.
the (3 chains of LFA-1 and Mo-1 had similar MM and IEF 
patterns. We extended these data by establishing that the (3 
chains of these antigens had exactly the same degree of re­
linked glycosylation and that both (3 chains were equally sensi­
tive to Endo-F treatment, The differences in MM of the a 
chains could not be attributed to differences in N-linked gly­
cosylation because after Endo-F treatment the digestion prod­
ucts still differed significantly in MM. The similarity of the (3 
chains was confirmed further by tryptic peptide maps which 
showed that the |3 chains of LFA-1 and Mo-1 also had identical 
protein backbones. In contrast, the protein backbones of both 
a  chains were completely different. In spite of their structural 
similarities and the finding that both molecules when ex­
pressed on granulocytes act as adhesion molecules [7, 24], 
Mo-1 and LFA-1 differ in other biological functions.
It is shown that LFA-1 is also required for monocyte-T cell 
interactions. Monocyte-dependent specific proliferative T cell 
responses to the soluble antigens TT or HPH were abrogated 
strongly by mAb against LFA-1. Interestingly, anti-LFA-1 
antibodies also completely inhibited the PWM-driven specific 
antibody production to HPH and TT in vitro. In contrast, 
Bear-1 and anti-Mo-1 had no effect on antigen-specific lym­
phocyte proliferation or specific antibody production in vitro. 
Thus, in spite of its identical (3 chain, Mo-1 was not associated 
with monocyte-T helper cell interaction.
LFA-1, Mo-1 and p!50,95 are related structurally. All 3 
molecules are also associated with adhesion functions of 
granulocytes. On the other hand, the present findings indicate 
that LFA-1 and Mo-1 are completely different in the biological 
functions described here. These differences may be related to 
their different a chains, which may recognize specific counter­
structures. Recent studies carried out in patients who are defi­
cient for LFA-1, Mo-1 and pl50,95 have shown that the identi­
cal (3 subunit seems to be required for the surface expression of 
the a-(3 heterodimeric complexes [8, 24].
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Biosynthesis of complement protein D by HepG2 cells: a 
comparison of D produced by HepG2 cells, U937 cells 
and blood monocytes*
The biosynthesis of complement protein D of the alternative pathway by HepG2 
cells, a human hepatocyte cell line, was studied and compared to the biosynthesis of D 
by U937 cells and blood monocytes. Increasing amounts of antigenic D were detected 
in HepG2 cell culture supernatants by radioimmunoassay. The kinetics of D synthesis 
and secretion by HepG2 cells was followed in a pulse-chase study using [35S]cysteine. 
As analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed 
by autoradiography, only a single D band was seen intra- and extracellularly and both 
forms had the same apparent molecular weight as D synthesized by U937 cells or 
purified from serum. Treatment of HepG2 and U937 cells with canavanine, an 
arginine amino acid analog, to inhibit intracellular processing resulted in slight 
depression of the apparent molecular weight of D synthesized by these cells. D 
synthesized by blood monocytes had an apparent molecular weight similar to that 
synthesized by HepG2 and U937 cells, suggesting that these cell lines do not synthe­
size and process D differently than normal monocytes. The data demonstrate that the 
hepatocyte is a site of D synthesis and suggest that D is not synthesized as a precursor 
molecule.
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1 Introduction
Studies on the biosynthesis of complement proteins (reviewed 
in [1]) have shown that the liver and cells of the monocyte/ 
macrophage series are the major sites of synthesis, although 
other cell types also synthesize certain complement proteins 
[2, 3]. Complement protein D of the alternative pathway has 
been the subject of limited biosynthetic study [4-6], however, 
recent work has demonstrated that U937 cells, a human mono­
cyte cell line, synthesize D [7]. Several questions were raised 
by this study, concerning the existence of a biosynthetic pre­
cursor, tissue specific differences in the post-translational pro­
cessing and synthesis of D by hepatocytes.
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